At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 118 enrolled
Drug / intervention
Torsemide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial
The University of Texas Health Science Center, Houston·interventional·Posted Jun 27, 2016·Updated Apr 10, 2019
In Brief
A Phase 2 clinical trial evaluating Torsemide and Placebo for Preeclampsia. Completed, enrolled 118 participants across 1 site.
Detailed Summary
Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionJul 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJun 27, 2016
Enrollment StartAug 1, 2016
Primary CompletionJul 28, 2017
Study CompletionSep 9, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.0 years ago
Interventions
Torsemidedrug
Placebodrug